Quick View: Lupin Achieves Three New Generic Approvals In The US Highlighting Continued Interest In Expanding Generics Portfolio
Pharmaceuticals / United States / Thu 18 Jan, 2024
The Latest: On January 14 2024, Lupin announced that it had received US FDA approval to market a generic version of propranolol hydrochloride extended-release capsules, used in the treatment of migraine and hypertension. The approval is significant as Lupin can offer a more affordable alternative to ANI Pharmaceuticals' Inderal LA extended